Physician profile
Shekeyla Young
NPI 1013586445
$3,615.32
in general payments reported to CMS, 2019-2025
14 companies · $19.61 in 2025
The $19.61 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,158 · 2022: $2,156 · 2023: $265 · 2024: $16.54 · 2025: $19.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $722.19 | 2021-2023 | Rexulti |
| Alkermes, INC. | $715.09 | 2021-2023 | Lybalvi, Aristada |
| Abbvie INC. | $627.88 | 2021-2024 | |
| Corium, LLC | $310.97 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $249.63 | 2021-2025 | Austedo Xr, Uzedy |
| Lundbeck LLC | $247.97 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $237.21 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $194.91 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $171.49 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.36 | 2022 | |
| Ironshore Pharmaceuticals INC. | $33.02 | 2022 | |
| Alfasigma USA, INC. | $23.81 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.06 | 2022 | |
| Livanova USA, INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shekeyla Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.